ClinicalTrials.gg
RecruitingNCT07737951Updated Aug 14, 2026

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

An interventional study of Tai Chi and Health Education in Hormone Receptor Positive Breast Carcinoma, Postmenopausal and Breast Cancer, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Breast Neoplasms by Thomas Jefferson University — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Thomas Jefferson University.

Planned enrollment
6th of 15
40 · median 25
Started
2026
the only one that year
No phase
10 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Breast Neoplasms by Thomas Jefferson University, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 20th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 20 studies in Breast Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by Thomas Jefferson University, or all of them as a file.
02

Study summary

The objective of the pilot RCT is to evaluate the feasibility and acceptability of a Tai Chi intervention "TaiChi4Joint" vs. an HE AC group for relieving AIIA in women with hormone receptor positive stage I-III BCa. The investigators will pilot test our data collection for mechanism measures via three innovatively integrated biobehavioral pathways.

Read the detailed description

40 patients from Thomas Jefferson University with a diagnosis of stage I-III hormone receptor-positive breast cancer who are postmenopausal, currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation, report joint pain that started or worsened after initiation of AI therapy, and report worst pain in the past week of ≥3 on the Brief Pain Inventory (BPI) 0-10 scale, indicating at least moderate pain. Eligible participants must be able to complete study procedures in English, be willing to be randomized in a 1:1 ratio to the intervention or attention control group, and adhere to study procedures. Participants will be excluded if they are currently engaged in regular structured moderate- or vigorous-intensity exercise totaling ≥150 minutes per week over the past 3 months, or participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months.

BCa patients with AIIA during the first 2 years of AI initiation will be equally randomized to either the TaiChi4Joint group or a health education AC group for 12 weeks.

TaiChi4Joint Group: Routine virtual Tai Chi group classes via Zoom for 1 hour, twice a week, for 12 weeks, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow-up. Health Education Attention Control Group: Routine virtual AC classes delivered remotely, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow up.

Primary Objectives: Examine the feasibility and acceptability of the RCT design and implementation Feasibility will be measured through consent rate, treatment attendance and retention.

Secondary Objectives: Examine the acceptability of the interventions. Acceptability will be indicated by participants-reporting treatment satisfaction using a standardized measure. Patient perceived creditability of the intervention, and patients' fidelity of the intervention and teleassessment will also be measured.

03

Conditions studied

  • Hormone Receptor Positive Breast Carcinoma
  • Postmenopausal
  • Breast Cancer

Browse trials for

Keywords

  • Anatrozole
  • Letrozole
  • Exemestane
  • Tai Chi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:

  • Age ≥18 years
  • Diagnosis of stage I-III hormone receptor-positive breast cancer
  • Currently receiving an aromatase inhibitor (anastrozole, letrozole, or exemestane) or within 5 years of initiation
  • Report joint pain that started or worsened after initiation of AI therapy
  • Report worst pain in the past week ≥3 on the BPI (0-10 scale)
  • Able to complete study procedures in English
  • Willing to be randomized to an intervention or attention control group and adhere to study procedures

Exclusion criteria

Exclusion Criteria:

-An individual who meets any of the following criteria will be excluded from participation in this study:

  • Undergoing active cancer treatment (excluding endocrine therapy)
  • Uncontrolled cardiac or pulmonary disease that would limit safe participation
  • Currently engaged in regular structured moderate- or vigorous-intensity exercise (e.g., brisk walking, jogging/running, cycling, swimming, aerobic classes, or resistance training) totaling ≥150 minutes per week over the past 3 months
  • Currently participating in Tai Chi, yoga, Pilates, or other structured mind-body practice ≥2 times per week over the past 3 months
  • Joint pain due to inflammatory arthritic conditions
  • Recent surgery or joint injection within the past 4-6 weeks
  • Initiation or dose change of or opioids within the past 4 weeks
  • Planned discontinuation of AI therapy within the next 6 months
  • This study is limited to women with breast cancer, as \<1% of cases occur in men and data on AIIA in male patients are limited
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    TaiChi4Joint

    Participants randomized to the TaiChi4Joint group will attend virtual Tai Chi classes via Zoom (1 hour, twice weekly for 12 weeks). At the first class, participants will review a Tai Chi safety and modifications handout. Using a manualized approach, each session includes structured objectives and activities to progressively learn simplified Tai Chi forms, with weekly verification of skill attainment. Six core elements are emphasized: (1) mindfulness (present-focused attention); (2) postural alignment (efficient, upright movement); (3) natural breathing (integrated with movement); (4) active relaxation (remaining relaxed while moving); (5) slow movement (building strength and endurance); and (6) integrated movement (coordinating functional movements).

    Behavioral: Tai Chi

  • Active comparator
    Health Education Attention Control

    To control for the attention that the TaiChi4Joint group receives, women randomized to the AC group will participate Routine virtual AC group classes via Zoom or via video link for 1 hour, twice a week, for 12 weeks, including survivorship content or healthy eating. The AC group is designed to control for attention and for expectations about getting some benefits from the treatment. The AC group is controlled for time and will also be 1 hour each time, twice a week, matching the frequencies and intensity of the intervention group.

    Behavioral: Health Education

Interventions

  • BehavioralTai Chi

    Routine virtual Tai Chi group classes via Zoom for 1 hour, twice a week, for 12 weeks, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow-up.

    Also known as: TaiChi4Joint

  • BehavioralHealth Education

    Routine virtual AC classes delivered remotely, three assessments: baseline, post-intervention follow-up and 2-month post-intervention follow up.

    Also known as: Health Education Attention Control Group

This study also gives Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Consent Rate

    Percentage of eligible participants who consent and enroll in the study.

    Time frame: Up to 6 months

  2. Engagement Rate

    Percentage of intervention sessions attended by enrolled participants.

    Time frame: 12 weeks

  3. Retention Rate

    Percentage of participants completing study follow up assessments.

    Time frame: 20 weeks

Secondary outcomes

  1. Client Satisfaction Questionnaire Score

    Participant reported satisfaction with the intervention measured using the Client Satisfaction Questionnaire. Acceptability will be 1) 80% of participants report a mean score of 4 or higher on participants' responses to study acceptability items on the Client Satisfaction Questionnaire. Client Satisfaction Questionnaire - 8 Item Version (CSQ-8) is a standardized measure of global satisfaction with services. It consists of 8 items, each rated on a 4-point Likert scale, with responses summed to yield a total score ranging from 8 (minimum) to 32 (maximum). Higher scores indicate a better outcome, reflecting greater client satisfaction with the services received.

    Time frame: 12 weeks

  2. Patient Perceived Credibility of the Intervention

    Primary benchmark for Credibility will be 2) a mean score of 4 or higher on participants 'responses to study items from the Credibility/Expectancy Questionnaire. 3) Chi-square tests will compare feasibility metrics by White vs. AA patients. Quantitative acceptability ratings will be summarized. The Credibility/Expectancy Questionnaire (CEQ) is a measure of treatment credibility and expectancy for improvement. It includes a Credibility subscale (3 items scored on a 1-9 scale) with total scores ranging from 3 (minimum) to 27 (maximum), and an Expectancy subscale (2 items scored on a 0-100 scale) with scores typically averaged to yield a range from 0 (minimum) to 100 (maximum). For both subscales, higher scores indicate a better outcome, reflecting greater perceived credibility of the intervention and stronger expectations that the treatment will be effective.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 2,668 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 11 months is below that.

Counting every sponsor, half of 2,778 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jul 30, 2026
StartActual
Jul 27, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07737951
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Jul 27, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Kuang-Yi Wen, PhD
Contact
Kuang-Yi.Wen@Jefferson.edu
215-503-4623
Kuang-Yi Wen, PhD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion